Invest in

Drug-Patent Cliffs

24.2%
1.1%
2.5%

Expiring Patents, Aspiring Generics

Big Pharma is headed for a big change. And generics are getting ready to grab their share. Branded drugs with sales of $86 billion would lose patent protection during 2013 to 2017.[1] Some of the most lucrative targets for generics in 2013 include Eli Lilly’s Cymbalta, Biogen Idec’s Avonex and Merck KGaA's Rebif. These drugs generated global sales worth $10 billion in 2012.[2] Generic drugs, once available, are typically 30% to 80% cheaper than the brand names, and can capture 80% of the market within the first year.[3] Which means the next few years hold an unprecedented growth opportunity for the generic drug industry. And that has investors feeling feverish. See more
24.2%
1.1%
2.5%
Invest in Thematic Portfolios
Create your own customizable basket of up to 30 stocks or ETFs for just $9.95.
Motif Index 1 YR Return
Drug-Patent Cliffs Benchmark
With this Motif, you can buy the following basket of stocks for just $9.95:
Weight Segment & Stocks Symbol 1 MO / 1 YR Return
100% Generic Drugs 25.2%
20.9% Taro Pharmaceutical Industries Ltd. TARO 7.6%
18.8% Dr. Reddys Laboratories Ltd. ADS RDY 18.2%
14.3% Mylan NV MYL 40.5%
11.6% Impax Laboratories Inc. IPXL 28.5%
8.4% Akorn Inc. AKRX 32.3%
6.7% Sagent Pharmaceuticals Inc. SGNT 48.0%
5.3% Abbott Laboratories ABT 18.8%
4.0% Mallinckrodt plc MNK 52.6%
3.0% Lannett Co. Inc. LCI 58.5%
2.5% Sanofi ADR (Sponsored) SNY 15.4%
1.7% Teva Pharmaceutical Industries Ltd ADR TEVA 15.0%
1.3% Cambrex Corp. CBM 20.7%
1.1% The Medicines Company MDCO 34.7%
0.4% Endo International PLC ENDP 81.8%

Quotes delayed 15 mins. Currently May 30, 2016 10:02:34 PM. Fields are marked with -- when data is unavailable.